Research programme: tissue protection technology - Lundbeck/Warren PharmaceuticalsAlternative Names: Tissue protection technology research programme - Warren Pharmaceuticals/Lundbeck; Tissue-protective cytokines
Latest Information Update: 23 Oct 2007
At a glance
- Originator Warren Pharmaceuticals
- Developer Lundbeck A/S; Warren Pharmaceuticals
- Class Cytokines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease; Neuroprotection